Randomized Trialmoderate evidence
Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial.
Nature metabolism·October 1, 2026·PMID 42823536
Why it mattersFibrotic MASH has limited approved therapies, and cellular senescence is implicated in hepatic inflammation and fibrosis. This proof-of-principle trial provides the first human evidence that senolytic therapy may improve fibrosis and MASH resolution, supporting further investigation of this mechanism in metabolic liver disease.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled